NeuroTherapia completes enrollment in Phase 1 first-in-human trial of NTRX-07

NeuroTherapia has completed enrollment of its Phase 1 single dose study of NTRX-07 in normal volunteers. Top line data is expected to be presented at the AAIC virtual meeting in July.

The study is designed to provide initial safety data and human pharmacokinetics of NTRX-07 in preparation for planned upcoming trials in patients.


Recent Posts

See All

PO Box 351

1500 Chagrin River Rd.

Gates Mills, OH  44040


©2019 by NeuroTherapia, Inc.